Amniotics AB (publ) (AMNI.ST)
SEK 0.01
(5.88%)
SEK 0.01
(5.88%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -30.87 Million SEK | 37.51% |
| 2022 | -49.39 Million SEK | 7.88% |
| 2021 | -53.62 Million SEK | -72.98% |
| 2020 | -31 Million SEK | -197.25% |
| 2019 | -10.42 Million SEK | -52.05% |
| 2018 | -6.85 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q3 | -6.66 Million SEK | 1.91% |
| 2023 Q4 | -5.82 Million SEK | 12.55% |
| 2023 Q1 | -11.85 Million SEK | -11.68% |
| 2023 Q2 | -6.79 Million SEK | 42.69% |
| 2023 FY | -30.87 Million SEK | 37.51% |
| 2022 Q3 | -17.05 Million SEK | -58.49% |
| 2022 Q4 | -10.61 Million SEK | 37.77% |
| 2022 Q2 | -10.75 Million SEK | 2.29% |
| 2022 Q1 | -11.01 Million SEK | 16.83% |
| 2022 FY | -49.39 Million SEK | 7.88% |
| 2021 Q1 | -12.5 Million SEK | 9.76% |
| 2021 Q4 | -13.23 Million SEK | -29.65% |
| 2021 Q3 | -10.21 Million SEK | 42.21% |
| 2021 Q2 | -17.67 Million SEK | -41.36% |
| 2021 FY | -53.62 Million SEK | -72.98% |
| 2020 FY | -31 Million SEK | -197.25% |
| 2020 Q4 | -13.85 Million SEK | -130.95% |
| 2020 Q3 | -5.99 Million SEK | -14.03% |
| 2020 Q2 | -5.26 Million SEK | 10.67% |
| 2020 Q1 | -5.88 Million SEK | 0.0% |
| 2019 FY | -10.42 Million SEK | -52.05% |
| 2018 FY | -6.85 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Active Biotech AB (publ) | -45.8 Million SEK | 32.598% |
| Biovica International AB (publ) | -124.82 Million SEK | 75.269% |
| Cantargia AB (publ) | -280.02 Million SEK | 88.976% |
| CombiGene AB (publ) | -35.66 Million SEK | 13.446% |
| Cyxone AB (publ) | -22.98 Million SEK | -34.282% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -164.343% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -88.255% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 66.226% |
| Fluicell AB (publ) | -26.55 Million SEK | -16.254% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 74.916% |
| Mendus AB (publ) | -101.61 Million SEK | 69.622% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 16.727% |
| I-Tech AB | 20.2 Million SEK | 252.799% |
| Intervacc AB (publ) | -102.85 Million SEK | 69.986% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -154.535% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 353.677% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -72.487% |
| OncoZenge AB (publ) | -15.9 Million SEK | -94.127% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -6947.945% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 92.047% |
| Lipum AB (publ) | -37.17 Million SEK | 16.967% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 87.582% |
| Ziccum AB (publ) | -21.41 Million SEK | -44.171% |
| BioArctic AB (publ) | 229.24 Million SEK | 113.466% |
| Genovis AB (publ.) | 61.5 Million SEK | 150.195% |
| Camurus AB (publ) | 431.44 Million SEK | 107.155% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 82.642% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 45.671% |
| Aptahem AB (publ) | -11.11 Million SEK | -177.786% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 90.072% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 82.818% |
| Kancera AB (publ) | -64.88 Million SEK | 52.426% |
| Saniona AB (publ) | -95.81 Million SEK | 67.78% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 26.888% |
| AcouSort AB (publ) | -17.08 Million SEK | -80.643% |
| Xintela AB (publ) | -54.08 Million SEK | 42.921% |
| Abliva AB (publ) | -95.5 Million SEK | 67.678% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 673.153% |
| 2cureX AB (publ) | -32.51 Million SEK | 5.068% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -140.645% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 93.378% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 96.288% |
| Biosergen AB | -27.03 Million SEK | -14.177% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -86.83% |
| Corline Biomedical AB | -1.8 Million SEK | -1606.468% |
| NextCell Pharma AB | -41.95 Million SEK | 26.43% |
| Nanologica AB (publ) | -75.15 Million SEK | 58.926% |
| LIDDS AB (publ) | -40.2 Million SEK | 23.22% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 90.557% |
| BioInvent International AB (publ) | -330.3 Million SEK | 90.654% |
| SynAct Pharma AB | -215.81 Million SEK | 85.696% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 29.927% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -30.05% |
| Alzinova AB (publ) | -16.48 Million SEK | -87.318% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 71.754% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 87.608% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -210.876% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 72.759% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -46.366% |
| Simris Alg AB (publ) | -37.3 Million SEK | 17.25% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 79.671% |